Showing results (1-10 of 157) with videos related to
Sort By:
Pageof 16
Expert Opinion on Therapeutic Patents|June 7, 2025
Nurr1 modulators - a patent review (2019-present)Markus Egner, Daniel MerkJournal of the American Chemical Society|November 4, 2025
De Novo Discovery of α,α-Disubstituted α-amino Acid-Containing α-helical Peptides as Competitive PPARγ PPI InhibitorsMaxwell Sigal, Markus Egner, Chikako Okada, et al.Journal of Medicinal Chemistry|February 7, 2025
A Nurr1 Agonist Derived from the Natural Ligand DHI Induces Neuroprotective Gene ExpressionMarkus Egner, Romy Busch, Úrsula López-García, et al.Journal of Medicinal Chemistry|November 24, 2025
Structural Tuning of Partial RXR Agonism and AntagonismMax Lewandowski, Marie Granger-Rivière, Domenic Mayer, et al.Journal of Medicinal Chemistry|September 26, 2023
Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand DihydroxyindoleMinh Sai, Jan Vietor, Moritz Kornmayer, et al.Methods in Molecular Biology (Clifton, N.J.)|July 25, 2018
Development of Nuclear Receptor ModulatorsSimone Schierle, Daniel MerkJournal of Medicinal Chemistry|November 2, 2023
Exploring Fatty Acid Mimetics as NR4A LigandsTanja Stiller, Daniel MerkMethods in Molecular Biology (Clifton, N.J.)|May 2, 2019
Hybrid Reporter Gene Assays: Versatile In Vitro Tools to Characterize Nuclear Receptor ModulatorsJan Heering, Daniel MerkChemical Communications (Cambridge, England)|March 31, 2023
Opportunities and challenges in targeting orphan nuclear receptorsLaura Isigkeit, Daniel MerkExpert Opinion on Therapeutic Patents|July 13, 2019
Therapeutic modulation of retinoid X receptors - SAR and therapeutic potential of RXR ligands and recent patentsSimone Schierle, Daniel MerkPageof 16